EASTERN COOPERATIVE ONCOLOGY GROUP

描述（由申请人提供）：阿尔伯特·爱因斯坦医学院癌症中心（AECC）是自1971年以来一直持续资助的NCI指定癌症中心。 我们的具体目标是通过在可行的情况下进行具有广泛应用潜力的翻译成分的创新临床试验来改善癌症的治疗和我们对其生物学的理解。 患者从四家附属医院招募，每年约有4000名新的癌症患者，有25名全职教职员工和20名血液学/肿瘤学研究员，由18名研究人员提供支持。 在上一个资助周期，AECC成员撰写或共同撰写了41篇与ECOG研究相关的手稿和25篇摘要，招募了332名ECOG/CTSU试验患者，主持或共同主持了23项研究（包括两项试验[E1199，E2197]，累积超过8000例患者），启动或报告了4项新的ECOG试验，这些试验部分或全部基于AECC初步研究（E1199，E3198，E3493，E1494），并在乳腺（J. Sparano），胃肠道（L. Augenlicht）、白血病（R. Gallagher），淋巴瘤（J. Sparano）和胸部委员会（S.凯勒河Perez-Soler）。 AECC研究人员还获得了资金，以支持与ECOG研究相关的白血病，妇科癌症和胃肠道癌症的转化研究。 其他活跃的临床研究项目包括一项实验性治疗项目，该项目每年招募约100名患者进行I期研究，并参与II期CTEP联盟，提供一个促进可用于ECOG的药物开发的环境;这方面的例子包括几项ECOG研究，包括BMS-247550（E2103、E3800、E2301），这些研究在AECC进行了I-II期开发。 AECC为130万种族和经济多样化的人口提供服务，其中70%的居民是少数民族，31%的居民生活在贫困线以下，ECOG/CTSU试验中近70%的少数民族招募反映了这一点。 在附属市立医院建立临床研究项目和社区肿瘤学项目将有助于进一步提高少数族裔的应计费用。 招聘一位国际公认的医生-科学家（R。Perez-Soler）担任内科肿瘤学系主任和癌症中心副主任的同时，还招聘了17名新的教员，这将进一步加强研究人员的积极核心，并提高该小组对ECOG的贡献。

DESCRIPTION (provided by applicant): The Albert Einstein College of Medicine Cancer Center (AECC) is an NCI-designated Cancer Center that has been continuously funded since 1971. Our specific aims are to improve the treatment of cancer and our understanding of its biology by conducting innovative clinical trials with translational components when feasible that offer the potential for broad application. Patients are recruited from four affiliated hospitals that see approximately 4000 new cancer patients each year, with 25 full time faculty members and 20 hematology/oncology fellows supported by 18 research staff. During the last grant cycle, AECC members authored or co-authored 41 manuscripts and 25 abstracts related to ECOG studies, enrolled 332 patients on ECOG/CTSU trials, chaired or co-chaired 23 studies (including two trials [E1199, E2197] that accrued over 8000 patients), initiated or reported four new ECOG trials that were based partly or wholly on AECC pilot studies (E1199, E3198, E3493, E1494), and provided scientific leadership in the breast (J. Sparano), gastrointestinal (L. Augenlicht), leukemia (R. Gallagher), lymphoma (J. Sparano), and thoracic committees (S. Keller, R. Perez-Soler). AECC investigators also secured funding to support translational studies in leukemia, gynecological cancer, and gastrointestinal cancer associated with ECOG studies. Other active clinical research programs include an experimental therapeutics program that recruits approximately 100 patients per year on phase I studies, and participation in a phase II CTEP consortium, providing an environment that fosters drug development that may be taken to ECOG; examples of this include several ECOG studies that include BMS-247550 (E2103, E3800, E2301), which underwent phase I-II development at AECC. The AECC serves an ethnically and economically diverse population of 1.3 million people, with 70 percent of residents being minority and 31 percent living below the poverty level, as reflected by nearly 70 percent minority recruitment on ECOG/CTSU trials. The establishment of a clinical research program in an affiliated municipal hospital and a community oncology program will serve to further enhance minority accrual. The recruitment of an internationally recognized physician-scientist (R. Perez-Soler) as Chairman of Department of Medical Oncology and Associate Cancer Center Director in July 2001 has been accompanied by recruitment of 17 new faculty members that will serve to further strengthen the active core of investigators and enhance the group's contributions to ECOG.